Table 2. Primary Endpoints Through 52 Weeks Post-Randomization Among 99 Children Retained on a Ritonavir-Boosted Lopinavir-Based Regimen (Control Group) and 96 Children Switched to a Nevirapine-Based Regimen (Switch Group).

	Control group	Switch group	p-value
N	99	96
Probability of lost to follow-up by 52 weeks	0.031	0.053	0.46
(95% CI)	(0.008 – 0.080)	(0.020 – 0.110)
N lost to follow-up before 52 weeks	3	5
Probability of mortality by 52 weeks	0.020	0.021	0.97
(95% CI)	(0.004 – 0.065)	(0.004 – 0.068)
N died	2	2
Probability of HIV-1 RNA > 50 copies/ml*	0.576	0.438	0.02
(95% CI)	(0.470 – 0.668)	(0.334 – 0.537)
N with > one measurement >50 copies/ml	55	40

^*Three children (2 in the control and 1 in the switch group) were missing virologic data and were excluded. Virologic data through 52 weeks post-randomization or up to the time of death or censoring were included. Probabilities are calculated using Kaplan-Meier methods and are compared across group using log-rank tests.